PMS62 Impact of Rheumatoid Arthritis on Self-Reported Work Productivity, Disease Severity And Adherence In an Employed Population  by Kamal, K.M. et al.
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 1 – A 3 0 7  A163
Muscular-skeletal DisorDers – Patient-reported outcomes & Patient 
Preference studies
PMs60
Biologic Discontinuation in rheuMatoiD arthritis: exPerience FroM 
canaDian clinics
Choquette D.1, Coupal L.1, Laliberté M.2, Desjardins O.2
1Institut de Rhumatologie de Montréal, Montreal, QC, Canada, 2AbbVie, Saint-Laurent, QC, 
Canada
OBJECTIVES: The purpose of this study was to describe biologic discontinuation 
and assess the predictors of discontinuation in Canadian rheumatoid arthritis (RA) 
patients. METHODS: In this prospective cohort study, adult patients included in the 
RHUMADATA database with a diagnosis of RA and treated with at least one biologic 
since 2003 were selected. The RHUMADATA database includes clinical, laboratory 
and socioeconomic information of patients with rheumatic diseases followed in 
three Canadian rheumatology centers (Montreal, Quebec and Rimouski). Patients 
were followed for three years after therapy initiation or until treatment discontinu-
ation, as measured using pharmacy records. Time to discontinuation and predic-
tors of treatment discontinuation were explored using Cox proportional hazards 
models. RESULTS: A total of 623 eligible patients were treated with at least one 
biologic. The average age was 53.2 years (SD= 12.4), 77% were women and patients 
had been diagnosed for an average of 7.7 years. The average time on treatment for 
the first biologic agent was 1.7 years (SD= 2.1). In all, 233 (37%), 326 (52%), 405 (65%), 
and 438 (70%) patients had stopped their first biologic after 6, 12, 24, and 36 months, 
respectively. In time-to-event analyses (Cox proportional hazard models), type of 
work [part time vs. full time; hazard ratio (HR): 1.57; 95% confidence interval (CI): 
1.05-2.34] and income [$20,000 to $40,000 vs. less than $20,000 (HR: 1.35; 1.01-1.80) 
and $80,000 to $100,000 vs. less than $20,000 (HR: 2.16; 1.23-3.80)] were significantly 
associated with biologic discontinuation over the complete treatment duration. The 
number of disease-modifying antirheumatic drugs used (HR: 0.89; 0.80-0.99) and 
use of methotrexate (yes vs. no; HR: 0.80; 0.64-0.99) were associated with a reduced 
risk of biologic discontinuation. CONCLUSIONS: In this real-life Canadian study, 
high biologic discontinuation rates were observed. This study also suggests that 
many clinical and socioeconomic variables are predictors of biologic discontinu-
ation in RA patients.
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OBJECTIVES: Rheumatoid arthritis (RA) is a chronic inflammatory disorder that 
affects the lining of joints, causing painful swelling that can result in bone ero-
sion and joint deformity. Patient adherence to medications can help reduce or 
lessen inflammation; however, non-adherence and frequent switching are rec-
ognized problems in patients with RA. The objectives of this study are to bet-
ter understand patients’ reason(s) for being non-adherent and/or switching and 
physicians’ reasons for recommending a switch. METHODS: We extracted 300 
records for RA patients from a unique database of physician-patient interactions 
(RealHealthData). Using Atlas.ti, we analyzed these records to analyze trends for 
medication switches and/or non-adherence, i.e., when, why and how patients 
stopped or switched their medication. In addition, we analyzed physicians’ noted 
reasons for switching. RESULTS: On average, patients were 53 years old (±10). 
Patients’ functional disability was similar to the general RA population, with a 
noted variability of swelling and joint pain. The medications prescribed to the 
patients included: methotrexate (22%), Orencia (18%), Remicade (14%), Plaquenil 
(14%), Humira (13%) Enbrel (8%), Acterma (6%) and CellCept (5%). Patients’ reported 
reasons for switching and/or non-adherence included: increased pain/swelling 
(34%), feeling the medication is not working and/or continual progression of 
symptoms (35%) and adverse reaction to medication such as itching (11%) and 
GI complications (11%). Of the physicians who recommended switching, reasons 
for switching their patients’ medications included potential toxicities associated 
with drugs (46%) and observed disease progression (34%). CONCLUSIONS: It is 
critical to better understand patients’ and physicians’ reasons for switching medi-
cation for chronic disease like RA. The more we know about reasons for behavior, 
the more we can actively plan and organize research, development and outreach 
that is patient-centric and clinically meaningful. Our results demonstrate that 
using physician-patient interaction data can add tremendous value to outcomes 
researchers and healthcare decision makers.
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OBJECTIVES: To study the impact of rheumatoid arthritis on self-reported work 
productivity, disease severity and adherence in an employed population METHODS: 
A total of 1,041 patients with rheumatoid arthritis (RA) were identified from a list of 
3000 patients (18-65 years) from a Specialty Pharmacy database. Survey to the RA 
sample included the Work Productivity and Activity Impairment (WPAI) question-
naire, Health Assessment Questionnaire (HAQ) and Modified Morisky Scale (MMS). A 
demographic survey was also administered. Survey responses were linked to clinical 
measures obtained from the Specialty Pharmacy database. Univariate and multi-
variate regression analyses were conducted using SPSS version 22.0. RESULTS: The 
response rate was 30.45% (n= 317) and 57.4% (n= 174) reported as being employed. 
Mean age and disease duration of employed patients were 54.09+9.97 years and 
15.21+9.11 years, respectively. Employed patients were mostly female (66.5%), mar-
OBJECTIVES: Bisphosphonates are anti-osteoporosis medication. This study evalu-
ated the cost-effectiveness of the use of bisphosphonates in secondary prevention 
of hip fracture in a naturalistic setting from the payer perspective. METHODS: Using 
the 1997-2007 Taiwan’s National Health Insurance research database, we identified 
patients with the first-ever hospitalization experience for hip fracture between 
1998 and 2000. The patients who received bisphosphonates within the first year of 
hip fracture were grouped into “bisphosphonates cohort”; those who received no 
anti-osteoporosis medications were grouped into “untreated cohort”. The date of 
the hip fracture served as the date of cohort entry. The two cohorts were followed up 
for hip re-fracture and osteoporosis-related medical costs. A Cox regression model 
was used to compare the risk of hip re-fracture and a generalized linear model was 
used to compare the osteoporosis-related costs between the cohorts. RESULTS: 
Among 3,427 patients identified, 161 received bisphosphonates and 3,266 were 
left untreated. The mean follow-up period of the bisphosphonates cohort and the 
untreated cohort were 5.11 and 4.72 years. There was no significant difference in 
the risk of re-fracture between the two groups (adjusted hazard ratio = 1.24, 95% CI 
0.87-1.78, p= 0.227). However, the osteoporosis-related costs of the bisphosphonates 
cohort were significantly higher than the untreated cohort (the average incremen-
tal cost was 29,227 point values, 95% CI 14,890-43,564, p< 0.001). Further analysis 
showed that the use of bisphosphonates is likely to be cost-saving from a one-year 
perspective; the probability of cost-saving was 73.8%. CONCLUSIONS: This study 
found the use of bisphosphonates for the secondary prevention of hip fracture was 
cost-ineffective in a naturalistic setting.
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BACKGROUND: Rheumatoid arthritis (RA) is a common autoimmune disease associ-
ated with considerable morbidity rates and diminished quality of life. For patients 
who have an inadequate response to disease-modifying antirheumatic drugs 
(DMARDs), the use of biologic agents and JAK inhibitor has proved to be effective 
as second-line treatment. [1]. OBJECTIVES: To evaluate the cost-effectiveness of 
Tofacitinib as second line treatment vs using the standard biological therapies as 
second line treatments in patients with moderate RA after failure of DMARDs in 
Guatemala Health Care System (IGSS) in 2014. METHODS: A patient-level simula-
tion model was used to evaluate costs and health benefits. This cost-effectiveness 
model compares two sequences of treatments: one using Tofacitinib as second line 
treatment followed by biological therapies (Tofacitinib-Infliximab-Adalimumab-
Etanercept-Tocilizumab-Rituximab-salvage therapy ) and the other using the same 
biologic therapies scheme but excluding Tofacitinib; these schemes are defined 
according to experts opinion from IGSS [2]. All patients received concomitant treat-
ment with methotrexate. Model inputs are: age, weight, initial HAQ score, severe 
adverse events (SAE) and clinical response to short and long term treatment; rand-
omized controlled trials were used as a source information when local information 
was not available [3,4]. HAQ scores were used to calculate utilities, measured in 
QALYs [5,6,7]. Only direct costs were considered using institutional databases from 
2014. [8]. Annual discount rate was 5%, the time horizon is to lifetime. RESULTS: 
Total cost and total QALY per patient in a lifetime period are estimated to be $213,009 
and 8.83 QALY for the treatment sequence with Tofacitinib; $222,145 and 8.52 for 
treatment sequence with biologic therapy only. The cost savings from the treatment 
sequence with Tofacitinib are 15.2% in the first year, 15.0% in 5 year and 10.7% in 
ten years. CONCLUSIONS: For the IGSS, the sequence initiating with Tofacitinib is 
a cost-saving alternative compared with the standard biologic therapy
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OBJECTIVES: Osteoarthritis is the most common form of arthritis, affecting 27 mil-
lion individuals in the United States. This study assessed incremental workplace 
absenteeism associated with osteoarthritis over one year. METHODS: Data from 
the 2011 Medical Expenditure Panel Survey (MEPS) was used for analyses. Sample 
inclusion criteria were being employed and at least eighteen years old. Individuals 
suffering from osteoarthritis were identified based on International Classification 
of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) diagnosis code of 715 in 
claims. Exclusion criteria were missing information on any variable. A zero inflated 
negative binomial regression was used with annual days missed at work as the 
response variable and a binary variable indicating osteoarthritis as the primary 
predictor. Covariates in the model adjusted for age, sex, education, race, marital 
status, occupation, region, insurance, hypertension, diabetes, anxiety, asthma, 
degree, hyperlipidemia and Charlson Comorbidity Index score. To account for the 
complex survey sample, sampling weights were incorporated in the model. Analyses 
were carried out using STATA for UNIX version 12.1 with an a priori alpha level of 
0.05. RESULTS: Among 10,597 individuals in the sample, 386 individuals had osteo-
arthritis. One-half of the sample was 47 years or younger, 54.43% were females, and 
70% were Caucasians. The expected number of days absent for individuals with 
osteoarthritis was 1.36 times the expected number of days absent for individuals 
without osteoarthritis (p= 0.038). Incremental annual days missed at work was 2.08 
days for individuals with osteoarthritis as compared to individuals without osteoar-
thritis (p= 0.037). Among covariates that were significant, expected number of days 
absent for individuals with hypertension was 1.37 times the expected number of 
days absent for those without hypertension (p< 0.01). The expected number of days 
absent for females was 1.54 times the expected number of days absent for males 
(p< 0.001). CONCLUSIONS: Osteoarthritis diagnosis is associated with significant 
incremental work absenteeism.
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OBJECTIVES: The aim of this study was to investigate the impact of chronic auto-
immune diseases, mainly rheumatoid arthritis (RA), on functional status among 
patients in Slovakia. METHODS: Patients were prospectively recruited in the 
National Institute for Rheumatic Diseases in Slovakia during 2014 and data from 
patients on disease impact on their life were collected from physicians through a 
specifically designed questionnaire. Functional status and disability assessments 
were conducted among patients with RA using the Stanford Health Assessment 
Questionnaire (HAQ). RESULTS: The sample (100 respondents) was predominantly 
female (82%) with diagnosis of RA (86%). The average age was 51 with 14-year dura-
tion of the disease average. Thirty-eight percent of patients had osteoporosis, 21% 
a cardiovascular disease and 29% patients underwent surgery due to autoimmune 
diseases – 3 times on average. The most common symptom, occurring more than 
once a week, was fatigue. Patients reported also reduced physical activity, pain 
and specifically joint pain. Manifestations of the disease were on average at a mild 
intensity. Full work disability was more common (37%) than partial work disability 
(29%) in the sample. HAQ final score ranged from 0 (no disability) to 3 (severe dis-
ability) with average HAQ score 1.35 (SD= 0.59). Majority of patients reported some 
or much difficulty in all HAQ domains and the highest disability was found for the 
domains of reach (score 1.59) and grip (1.54). HAQ score is increasing with the dis-
ease duration: average HAQ score in patients with RA lasting less than 10 years was 
significantly lower (1.17) than in patients with the disease duration of 20 years and 
more (1.61). CONCLUSIONS: Results indicate that chronic autoimmune diseases, 
mainly rheumatoid arthritis (RA), have negative impact on activities of daily living 
and the most commonly reported symptoms are fatigue and pain. Functional status 
is worsening with the duration of the disease.
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OBJECTIVES: The aim of this study was to investigate the socio-economic impact of 
chronic autoimmune diseases, mainly rheumatoid arthritis (RA) and work disabili-
ties, among patients in Slovakia. METHODS: Patients were prospectively recruited 
in the National Institute for Rheumatic Diseases in Slovakia during the year 2014 
and the data from patients on disease impact on their life were collected by con-
sulting physicians through a specifically designed questionnaire. RESULTS: The 
sample (100 respondents) was predominantly female (82%) with diagnosis of RA 
(86%). As many as 66% of the patients became permanently work disabled at the 
average age of 42 years, with full work disability being more common (37%) than 
partial work disability (29%). The occurrence of sick leave in the past 12 months 
among patients with a job was 48% with an average length of 30 days. Twenty-
three percent of respondents had to change their jobs due to the disease. Average 
personal expenses connected with the treatment in the last 3 months were 74 € , 
out of that the highest were their costs of traveling. 74% of respondents stated 
restrictive (52%) or very restrictive (22%) impact of the disease on their function-
ing, mostly in strenuous activities or sport. Three most frequently reported areas 
negatively affected by the disease were: social activities (reported by 63% respond-
ers), professional career (49%) and quality of a relationship with their partner (28%). 
Areas that have improved in comparison with the period when patients started 
their treatment were: communication with healthcare personnel and more effec-
tive therapies available. The support from patient organizations wasn’t perceived 
as significant. CONCLUSIONS: The occurrence of permanent work disability and 
sick leave was substantial in the sample. This study in patients with autoimmune 
chronic conditions - mainly RA, showed significant impact of the disease on work 
capabilities and socio-economic status.
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OBJECTIVES: Using an example of a new drug for rheumatoid arthritis which 
offers comparable effectiveness and side-effect point estimates to older drugs, we 
explore preferences for treatments labelled ‘new’. We then examine the persistence 
of preferences once ambiguity in the evidence base due to it being new is intro-
duced. METHODS: A representative Canadian population sample (n= 2837) was ran-
domized to one of three discrete choice experiment (DCE) designs, seeking choices 
between hypothetical treatments for rheumatoid arthritis with different levels of 
7 attributes: route and frequency of administration, chance of benefit, serious and 
minor side-effects, life expectancy, and uncertainty in benefit and side-effect esti-
mates. DCEs differed in whether the treatment was 1) described as new (recently 
available) or older (5 or 10 years), 2) whether a qualitative description describing 
the confidence in the evidence was included instead, or 3) both the length of time 
available and confidence in evidence was provided. We collected self-reports of 
respondent innovativeness, numeracy, and risk attitude. RESULTS: Overall, all 6 
consistent attributes influenced preferences for treatment. A preference for less 
ambiguity (more confidence) in benefit and side-effect estimates was observed, but 
no preference for a treatment labelled ‘new’ or ‘old’. Early adopters (n= 173) had a 
significant preference for ‘newer’ treatments relative to old treatments (B= 0.157, 
p= 0.045). The magnitude of preference for new treatments was comparable with 
preferences for reducing the risks of serious side-effects in this group. When the 
newness of the drug was combined with ambiguity in the evidence base, these 
preferences for ‘new’ treatments diminished. CONCLUSIONS: Preferences for inno-
vation in health care exist for some groups of people, but when presented with the 
implications of new treatments (increased ambiguity in evidence), these prefer-
ences diminished. Physicians should either avoid describing whether treatments 
are ‘new’, or qualify the implications of a ‘new’ treatment in terms of ambiguity in 
estimates of risks and benefits.
ried (77.9%), had college/graduate degrees (59.5%), and had income > $75,000 (58.7%). 
The mean HAQ scores was 0.48+0.55 with 79.2% (n= 137) having HAQ < 1, 18.5% 
(n= 37) between 1-2, and 2.3% (n= 4) > 2. 60.3% (n= 105) employed patients reported 
high knowledge and high motivation while only 7.5% (n= 13) reported low knowl-
edge and low motivation on MMS. Most employed respondents (90.4%, n= 150) did 
not miss work due to RA with mean hours lost in the last seven days reported as 
1.04+5.18 (0-40hrs). 54.4% (n= 93) reported working more than 40 hours over the past 
seven days. Employed patients reported mean score of 1.8+2.2 for work impairment 
and 2.27+ 2.35 daily activities impairment due to their RA (measured on a scale of 
0-10 where 0 was no problem and 10 was major problem). CONCLUSIONS: Within 
the employed population, RA seems to have little effect on absenteeism, work pro-
ductivity and daily activities. High motivation and knowledge (adherence) and low 
disease severity maybe significantly and independently contributing to a favorable 
patient-perceived work productivity.
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OBJECTIVES: To evaluate the relationship between medication adherence, disease 
severity and employment status in patients with rheumatoid arthritis METHODS: 
A list of 3000 patients (18-65 years) were identified from a Specialty Pharmacy data-
base. 1,041 patients with a diagnosis of rheumatoid arthritis (RA) were identified 
from the list and were invited to participate in a survey. The patients were mailed 
a cover letter, consent letter, and a demographic questionnaire. Additionally, the 
Work Productivity and Activity Impairment (WPAI) questionnaire (assess produc-
tivity losses), Health Assessment Questionnaire (HAQ; disease severity), Modified 
Morisky Scale (MMS; medication adherence) were administered. Survey responses 
were linked to clinical measures obtained from the specialty pharmacy data-
base. Descriptive and logistic regression analyses were conducted using employ-
ment status as an outcome variable and HAQ, adherence, and demographics 
as input variables. The statistical analyses were conducted using SPSS version 
22.0. RESULTS: The response rate was 30.45% (n= 317). Based on WPAI results, 
57.4% (n= 174) identified themselves as being employed. Differences in mean age 
and mean HAQ scores of employed (54.09 years; 0.48) and unemployed (64.13 years; 
0.96) were statistically significant (p< 0.001) while there was no difference in the 
disease duration (p= 0.494). 47.3% of unemployed and 21.8% employed had HAQ 
scores greater than 1. There was a statistically significant difference in employed 
vs. unemployed (p< 0.001) across disease severity based on HAQ. While there was 
no difference in the level of knowledge (p= 0.187), there was a statistically signifi-
cant difference (p< 0.001) in the level of motivation between employed (63.5% high 
motivation) and unemployed (82% high motivation) respondents. CONCLUSIONS: 
Study results showed that employed patients, while having similar disease dura-
tion and level of knowledge, reported lower motivation on the MMS adherence 
scale. Although these patients had less severe RA compared to unemployed, this 
could act as a potential barrier to chronic treatment management and needs to 
be assessed in clinical practice.
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OBJECTIVES: The ultimate goals in managing Rheumatoid Arthritis (RA) are prevent-
ing or controlling joint damage, preventing loss of function and decreasing pain. 
Assessment of disease activity is critical; therefore, guidelines recommend that 
physicians evaluate patients’ symptoms and severity. The objective of this study was 
to examine how often evaluation of disease activity and damage in patients with RA 
was documented by physicians during office visits. METHODS: We extracted 300 
records for RA patients from a unique database of physician-patient interactions 
(RealHealthData). Using Atlas.ti, we analyzed these records to evaluate how often 
the recommended assessments of disease activity was documented by physicians 
during office visits. RESULTS: Almost all physicians (92%) document the presence 
of actively inflamed joints (i.e., tender and swollen joint counts) and evidence of dis-
ease progression (i.e., loss of motion, deformity). However, only 28% and 18% docu-
ment duration of morning stiffness and fatigue respectively. And while limitation 
of function is explored, only 11% documented the degree of joint pain via a visual 
analog scale. Lastly, it was rare for physicians to document their own global assess-
ment of disease activity (5%) or the patient’s global assessment of disease activity 
(8%). CONCLUSIONS: The more we know about patients’ reported symptoms and 
outcomes, the more we can actively plan and organize research, development and 
outreach that is patient-centric and clinically meaningful. Successful treatment 
includes systematic and regular evaluation of disease activity and patient assess-
ments to help limit joint damage and functional loss. While many physicians are 
documenting the number of tender and swollen joints, loss of motion or deformity, 
a majority of physicians are not documenting patient-reported symptoms that are 
critical to disease monitoring such as morning stiffness, fatigue or overall degree of 
joint pain. Our results demonstrate there is room for improvement when it comes 
to documenting patient-reported outcomes in RA.
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